Product nameAnti-PFKM antibody
See all PFKM primary antibodies
DescriptionRabbit polyclonal to PFKM
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Cow, Dog, Pig
Recombinant fragment corresponding to Human PFKM aa 1-223.
- 293T, A431, H1299, HeLa, Molt-4, Raji cells
This product was previously labelled as Fructose 6 Phosphate Kinase
Storage instructionsShipped at 4°C. Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.21% Tris, 0.75% Glycine, 20% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab97353 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 85 kDa.|
PathwayCarbohydrate degradation; glycolysis; D-glyceraldehyde 3-phosphate and glycerone phosphate from D-glucose: step 3/4.
Involvement in diseaseDefects in PFKM are the cause of glycogen storage disease type 7 (GSD7) [MIM:232800]; also known as Tarui disease. GSD7 is an autosomal recessive disorder characterized by exercise intolerance with associated nausea and vomiting. Short bursts of intense activity are particularly difficult. Severe muscle cramps and myoglobinuria develop after vigorous exercise. Most patients obtain a "second wind" when the onset of exercise is followed by a brief rest period. In time patients adjust their activity level and are well compensated.
Sequence similaritiesBelongs to the phosphofructokinase family. Two domains subfamily.
- Information by UniProt
- 6 Phosphofructokinase Muscle Type antibody
- 6-phosphofructokinase antibody
- 6-phosphofructokinase muscle type antibody
ab97353 has not yet been referenced specifically in any publications.